It doesn't, but your answer is very interesting. We must build on the momentum to ensure that more medicines become available. I understand that very well.
However, my question was about your comments. You said that for a drug to be available at a lower cost, we need competition among companies, since competition would drive down costs. If only Canada amends its regime, how will that create more competition in the second-line medicine market?